H.C. Wainwright initiates coverage on Spero Therapeutics (NASDAQ: SPRO) with a Buy rating and a price target of $28.00.ANalyst Ed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE